首页 | 本学科首页   官方微博 | 高级检索  
     

华蟾素胶囊联合TN化疗方案对中晚期宫颈癌放疗患者血清SCC、TSGF水平及生存质量的影响
引用本文:李 茜1,刘春燕1,崔 健2. 华蟾素胶囊联合TN化疗方案对中晚期宫颈癌放疗患者血清SCC、TSGF水平及生存质量的影响[J]. 现代肿瘤医学, 2019, 0(6): 1052-1057. DOI: 10.3969/j.issn.1672-4992.2019.06.036
作者姓名:李 茜1  刘春燕1  崔 健2
作者单位:1.中日医院妇产科,北京 1000292.新疆生产建设兵团医院妇产科,新疆 乌鲁木齐 830002
摘    要:目的:探讨华蟾素胶囊联合TN化疗方案(紫杉醇+奈达铂)在中晚期宫颈癌放疗患者中的应用效果。方法:选取中晚期宫颈癌放疗患者71例,按照随机数字表法分组,对照组35例给予TN化疗方案治疗,观察组36例给予TN化疗方案+华蟾素胶囊治疗,观察比较两组临床疗效及治疗前后血清鳞状细胞癌相关抗原(SCC)、肿瘤特异性生长因子(TSGF)水平及生存质量各维度评分变化情况,并统计两组毒副反应发生情况及1年、2年、3年生存率。结果:观察组临床缓解率为83.33%(30/36),高于对照组57.14%(20/35)(P<0.05);治疗4个疗程后观察组血清SCC、TSGF水平低于对照组(P<0.05);观察组便秘、腹泻及恶心呕吐发生率与对照组比较,差异无统计学意义(P>0.05);观察组白细胞下降发生率为11.11%(4/36),低于对照组31.43%(11/35)(P<0.05);治疗4个疗程后观察组认知、角色、躯体、社会及情绪功能生存质量评分高于对照组(P<0.05);观察组1年生存率为91.67%(33/36)、2年生存率为86.11%(31/36)、3年生存率为77.78%(28/36),与对照组(91.43%、85.71%、74.29%)比较,差异无统计学意义(P>0.05)。结论:TN化疗方案联合华蟾素胶囊可降低中晚期宫颈癌放疗患者血清TSGF、SCC水平,提高其生存质量,疗效确切,安全性高。

关 键 词:宫颈癌  中晚期  华蟾素胶囊  TN化疗方案  血清SCC  TSGF  生存质量

Effect of combination of Toad capsule and TN chemotherapy on serum levels of SCC and TSGF and quality of life in patients with advanced cervical cancer
Li Qian1,Liu Chunyan1,Cui Jian2. Effect of combination of Toad capsule and TN chemotherapy on serum levels of SCC and TSGF and quality of life in patients with advanced cervical cancer[J]. Journal of Modern Oncology, 2019, 0(6): 1052-1057. DOI: 10.3969/j.issn.1672-4992.2019.06.036
Authors:Li Qian1  Liu Chunyan1  Cui Jian2
Affiliation:1.Department of Gynaecology and Obstetrics,Chinese and Japanese Hospital,Beijing 100029,China;2.Department of Gynaecology and Obstetrics,Xinjiang Production and Construction Corps Hospital,Xinjiang Urumqi 830002,China.
Abstract:Objective:To explore the application value of combination of Toad capsule and TN chemotherapy in treating patients with advanced cervical cancer.Methods:71 cases of advanced cervical cancer with radiotherapy were selected and divided into groups according to random numbers.35 cases in the control group were treated with TN chemotherapy,and 36 cases in the observation group were treated with TN chemotherapy+Toad capsule.The clinical effects and the levels of serum squamous cell carcinoma related antigen (SCC),tumor specific growth factor (TSGF) and the each dimension score of quality of life before and after the treatment of the two groups were compared.The incidence of adverse reactions and the 1-year,2-year,and 3-year survival rates of the two groups were also statistically analyzed.Results:The clinical remission rate in the observation group was 83.33%(30/36),higher than that in the control group 57.14%(20/35)(P<0.05).After 4 courses of treatment,the levels of serum SCC and TSGF in the observation group were lower than those in the control group(P<0.05).The incidence of constipation,diarrhea and nausea and vomiting in the observation group was not significantly different from that in the control group(P>0.05).The incidence of leukocyte decline in the observation group was 11.11%(4/36),lower than that in the control group 31.43%(11/35) (P<0.05).After 4 courses of treatment,the scores of cognition,role,body,society,and emotion of quality of life in the observation group were higher than those in the control group(P<0.05).The 1-year survival rate of the observation group was 91.67%(33/36),the 2-year survival rate was 86.11%(31/36) and the 3-year survival rate was 77.78%(28/36).The difference was not statistically significant compared with the control group (91.43%,85.71%,74.29%)(P>0.05).Conclusion:TN chemotherapy combined with Toad capsule can reduce the levels of serum TSGF and SCC in advanced cervical cancer patients with radiotherapy,and improve the quality of survival.It is effective and safe.
Keywords:cervical cancer   middle-later stage   Toad capsule   TN chemotherapy scheme   serum SCC   TSGF   quality of life
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号